Jericho, New York, Oct. 22, 2025 (GLOBE NEWSWIRE) — Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a developmental-stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, has engaged Strategic Investor Relations, LLC, a premier investor relations firm, to enhance Curanex’s visibility in the financial community and support its ongoing efforts to engage and educate current and potential investors about the Company’s innovative pipeline and strategic initiatives.
With this new partnership, Curanex aims to refine its communication strategies and investor relations activities to ensure stakeholders are fully informed and engaged with the Company’s progress and prospects. Strategic Investor Relations will assist Curanex in highlighting its botanical drug development approach, which encompasses high-efficacy botanical drugs with de-risked clinical pathways and its positioning in the rapidly expanding botanical drug market.
Curanex is advancing a robust pipeline targeting key inflammatory indications, including Ulcerative Colitis, Atopic Dermatitis, and Gouty Arthritis, leveraging decades of real-world use in China. The Company’s lead botanical candidate for Ulcerative Colitis is on track for IND submission in 2026.
Curanex’s founders have established a strong foundation in botanical drug innovation, drawing on extensive preclinical data across multiple indications, with the focus on de-risked development, and with botanical programs informed by over 30 years of clinical evidence in China.They bring a commitment for Curanex to regulatory compliance with the FDA.
“Engaging with Strategic Investor Relations represents an important step towards strengthening our relations with current and prospective investors and better communicating our financial story and market opportunities,” said Mr. Jun Liu, Chairman and Chief Executive Officer of Curanex Pharmaceuticals. “We are committed to enhancing our transparency and engagement with the investor community as we advance our drug development and deliver on our mission to transform inflammatory disease treatment. Together with the expertise of Strategic Investor Relations, we are confident in our ability to communicate our vision and clinical successes more effectively, driving enhanced shareholder value.”
Mr. Matthew Abenante, President of Strategic Investor Relations, commented, “We are thrilled to partner with Curanex Pharmaceuticals, a trailblazer in dual-modality therapeutics for inflammatory diseases. Curanex’s innovative botanical pipeline positions them uniquely for transformative growth. I am extremely excited about the future for Curanex as it continues to de-risk and advance its programs, ensuring the Company remains at the forefront of biopharmaceutical innovation.”
link